@misc{indiciae079587b8bcdd,
  title = {Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study.},
  author = {S Saji and T Yamashita and J Tsurutani and Y Sagara and H Shigematsu and T Takano and M Takahashi and K Araki and N Tamura and M Tsuneizumi and T Morimoto and S Yanai and A Kato and M Yamaguchi and S Kubo and Y Hasegawa and E Tokunaga and H Hasegawa and S Osaka and S Morita and K Sakai and N Masuda},
  year = {2026},
  doi = {10.1016/j.esmoop.2026.108325},
  url = {https://pubmed.ncbi.nlm.nih.gov/42480197/},
  note = {Source identifier: 42480197}
}